Email this article The Economic Evaluation of Rare Disease Medicines
(1) Faculty of Pharmacy, Jenderal Achmad Yani University
(2) Pharmacy Department, Medical Faculty, Tanjungpura University
(3) Pharmacy Department of Harapan Bangsa University
(4) Bachelor Program of Pharmacy, Jenderal Achmad Yani University
Abstract
Economic evaluation of rare diseases and orphan drugs has gained prominence among scientists, managers, and the general public. This challenging problem requires evaluation and analysis from a variety of perspectives. Economic assessment of technologies can support decision-making and resource allocation. The research objective describes and discusses several important issues when addressing economic evaluation in rare diseases and orphan drugs. The method used in this article review is to search the Pubmed, Scopus, and ScienceDirect databases using specific keywords for research articles published in English between 2016 and 2021. We found 537 studies that economically evaluated the cost of treating rare diseases. The selected studies met the eligibility criteria that had been established. To assess the quality of the selected papers, we used a 10-point checklist derived from Drummond's criteria for economic evaluation. Seven papers were reviewed from the initial 20 articles that met the eligibility criteria, and 537 records were initially found across the three databases. The quality of the selected papers ranged from 70% to 100% in meeting Drummond's 10-point checklist. The conclusion of this research is to consistently and continuously identify cost-effective and cost-saving solutions that may help achieve good clinical outcomes and reduce the burden of disease. Future research should focus on the clinical implementation of interventions along with accompanying economic evaluations.
Keywords
Full Text:
PDFReferences
Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023). Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges. International Journal of Environmental Research and Public Health, 20(6). https://doi.org/10.3390/ijerph20064732
Angelis, A., Tordrup, D., & Kanavos, P. (2015). Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy, 119(7), 964–979. https://doi.org/10.1016/j.healthpol.2014.12.016
Aranda-Reneo, I., Rodríguez-Sánchez, B., Peña-Longobardo, L. M., Oliva-Moreno, J., & López-Bastida, J. (2021). Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis. Value in Health, 24(3), 431–442. https://doi.org/10.1016/j.jval.2020.10.014
Beresniak, A., & Dupont, D. (2016). Is there an alternative to quality-adjusted life years for supporting healthcare decision making? Expert Review of Pharmacoeconomics and Outcomes Research, 16(3), 351–357. https://doi.org/10.1080/14737167.2016.1184975
Blonda, A., Denier, Y., Huys, I., & Simoens, S. (2021). How to Value Orphan Drugs? A Review of European Value Assessment Frameworks. Frontiers in Pharmacology, 12(May), 1–16. https://doi.org/10.3389/fphar.2021.631527
Café, A., Carvalho, M., Crato, M., Faria, M., Kjollerstrom, P., Oliveira, C., Pinto, P. R., Salvado, R., Dos Santos, A. A., & Silva, C. (2019). Haemophilia A: Health and economic burden of a rare disease in Portugal. Orphanet Journal of Rare Diseases, 14(1), 1–11. https://doi.org/10.1186/s13023-019-1175-5
Cai, X., Yang, H., Genchev, G. Z., Lu, H., & Yu, G. (2019). Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai. Orphanet Journal of Rare Diseases, 14(233).
Cannizzo, S., Lorenzoni, V., Palla, I., Pirri, S., Trieste, L., Triulzi, I., & Turchetti, G. (2018). Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open, 4(e00794). https://doi.org/i:10.1136/rmdopen-2018-000794
Chambers, J. D., Silver, M. C., Berklein, F. C., Cohen, J. T., & Neumann, P. J. (2020). Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. Journal of General Internal Medicine, 35(9), 2629–2636. https://doi.org/10.1007/s11606-020-05805-2
Chen, Y. (2022). Health technology assessment and economic evaluation: Is it applicable for the traditional medicine? Integrative Medicine Research, 11(1), 100756. https://doi.org/10.1016/j.imr.2021.100756
Chiu, A. T. G., Chung, C. C. Y., Wong, W. H. S., Lee, S. L., & Chung, B. H. Y. (2018). Healthcare burden of rare diseases in Hong Kong - Adopting ORPHAcodes in ICD-10 based healthcare administrative datasets Dr. Segolene Ayme. Orphanet Journal of Rare Diseases, 13(1), 1–8. https://doi.org/10.1186/s13023-018-0892-5
Davari, M., Nabizadeh, A., Kadivar, M., Asl, A. A., & Sarkheil, P. (2019). Healthcare resource utilization and cost of care for Gaucher patients in Iran. Journal of Diabetes and Metabolic Disorders, 18(1), 127–132. https://doi.org/10.1007/s40200-019-00399-x
Delaye, J., Cacciatore, P., & Kole, A. (2022). Valuing the “Burden” and Impact of Rare Diseases: A Scoping Review. Frontiers in Pharmacology, 13(June), 1–10. https://doi.org/10.3389/fphar.2022.914338
Desser, A. S., Gyrd-Hansen, D., Olsen, J. A., Grepperud, S., & Kristiansen, I. S. (2010). Societal views on orphan drugs: Cross sectional survey of Norwegians aged 40 to 67. BMJ (Online), 341(7774), 642–644. https://doi.org/10.1136/bmj.c4715
Dianingati, R. S., Riewpaiboon, A., & Youngkong, S. (2019). Indonesia Hospital Cost Analysis: a Micro-Costing Approach. Jurnal Kesehatan Masyarakat, 14(3), 376–382. https://doi.org/10.15294/kemas.v14i3.15627
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford: Oxford University Press.
Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007). Assessing the economic challenges posed by orphan drugs. International Jpurnal of Technology Assessment in Health Care, 23(1), 36–42.
Dussen, L. van, Biegstraaten, M., Hollak, C. E. M., & Dijkgraaf, M. G. W. (2014). Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet Journal of Rare Diseases, 14(9), 51. https://doi.org/doi: 10.1186/1750-1172-9-51.
Fakhri, M. A., Hanafiah Juni, M., Rosliza, A., & Faisal, I. (2017). Societal Perspective in Economic Evaluation. International Journal of Public Health and Clinical Sciences, 4(4), 2289–7577.
Fermaglich, L. J., & Miller, K. L. (2023). A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet Journal of Rare Diseases, 18(1), 1–8. https://doi.org/10.1186/s13023-023-02790-7
Friedlander, L., Berdal, A., Boizeau, P., Licht, B. A., Manière, M. C., Picard, A., Azzis, O., Vazquez, M. P., Alberti, C., & Molla, M. D. L. D. (2019). Oral health related quality of life of children and adolescents affected by rare orofacial diseases: A questionnaire-based cohort study. Orphanet Journal of Rare Diseases, 14(1), 1–13. https://doi.org/10.1186/s13023-019-1109-2
Galan, L., Gonzalez-Moreno, J., Martínez-Sesmero, J. M., Muñoz-Beamud, F., Santos-Rubio, M. D., Tran, D., Lebeau, P., Stewart, M., Mallaina, P., Tarilonte, P., Peral, C., & Rozenbaum, M. H. (2021). Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 21(5), 967–973. https://doi.org/10.1080/14737167.2021.1900738
Gammie, T., Vogler, S., & Babar, Z. U. D. (2017). Economic Evaluation of Community and Hospital Pharmacy Services: An Introductory Review. In Economic Evaluation of Pharmacy Services. Elsevier Inc. https://doi.org/10.1016/B978-0-12-803659-4.00002-3
Giudice, G., Filoni, A., Maggio, G., Bonamonte, D., & Vestita, M. (2017). Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds. BioMed Research International, 2017. https://doi.org/10.1155/2017/9567498
Gupta, A. Das, Bowman, L., D’Arsigny, C., & Archer, S. L. (2015). Soluble Guanylate Cyclase: A new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Handbook of Clinical Anaesthesia 3E, 97(1), 88–102. https://doi.org/10.1002/cpt.10.Soluble
Haendel, M., Vasilevsky, N., Unni, D., Bologa, C., Harris, N., & Rehm, H. (2020). How many rare diseases are there? Nat Rev Drug Discov, 19(2), 77–78.
Hagendijk, M. E., van der Schans, S., Boersma, C., Postma, M. J., & van der Pol, S. (2021). Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. European Journal of Health Economics, 22(6), 991–999. https://doi.org/10.1007/s10198-021-01303-2
HsuI, J. C., Wu, H.-C., Feng, W.-C., Chih-HoChou, EdwardChia-ChengLai, & ChristineY.Lu. (2018). Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan’s National Health Insurance Research Database. Plos One, September. https://doi.org/10.1371/journal.pone.0204206
Jalali, A., Rothwell, E., R., J., Anderson, R. A., Butterfield, R. J., & Nelson, R. E. (2020). Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy. Journal Pediatrics, 227, 274–280. https://doi.org/doi:10.1016/j.jpeds.2020.07.033.
Jo, C. (2014). Cost-of-illness Studies: Concepts, Scopes, and Methods. Clinical and Molecular Hepatology, 20(4), 327–337. https://doi.org/10.3350/cmh.2014.20.4.327
Jommi, C., Listorti, E., Villa, F., Ghislandi, S., Genazzani, A., Cangini, A., & Trotta, F. (2021). Variables affecting pricing of orphan drugs: the Italian case. Orphanet Journal of Rare Diseases, 16(1), 1–10. https://doi.org/10.1186/s13023-021-02022-w
Jönsson, B. (2009). Editorial: Ten arguments for a societal perspective in the economic evaluation of medical innovations. European Journal of Health Economics, 10(4), 357–359. https://doi.org/10.1007/s10198-009-0173-2
Kazi, D. S., Bellows, B. K., Baron, S. J., Shen, C., Cohen, D. J., Spertus, J. A., Yeh, R. W., Arnold, S. V., Sperry, B. W., Maurer, M. S., & Shah, S. J. (2020). Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation Journal, 14(141 (15)), 1214–1224. https://doi.org/10.1161/CIRCULATIONAHA.119.045093.Cost-Effectiveness
Korchagina, D., Millier, A., Vataire, A. L., Aballea, S., Falissard, B., & Toumi, M. (2017). Determinants of orphan drugs prices in France: A regression analysis. Orphanet Journal of Rare Diseases, 12(1), 1–11. https://doi.org/10.1186/s13023-016-0561-5
Makarova, E. V., Krysanov, I. S., Vasilyeva, T. P., Vasiliev, M. D., & Zinchenko, R. A. (2021). Evaluation of orphan diseases global burden. European Journal of Translational Myology, 31(2). https://doi.org/10.4081/EJTM.2021.9610
Marita, Z., Lubinga, S. J., Banken, R., RInd, D., Cramer, G., Synnott, P. G., Chapman, R. H., Khan, S., & Carlson, J. (2019). Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal DIsease. Value in Health, 22, 161–167.
Mazzucato, M., Minichiello, C., Vianello, A., Visonà dalla Pozza, L., Toto, E., & Facchin, P. (2022). Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study. Frontiers in Pharmacology, 13(September), 1–12. https://doi.org/10.3389/fphar.2022.940010
Mursinto, D., & Kusumawardani, D. (2016). Estimasi Dampak Ekonomi Dari Pencemaran Udara Terhadap Kesehatan Di Indonesia. Jurnal Kesehatan Masyarakat, 11(2), 163. https://doi.org/10.15294/kemas.v11i2.3677
Onakpoya, I. J., Spencer, E. A., Thompson, M. J., & Heneghan, C. J. (2015). Effectiveness, safety and costs of orphan drugs: An evidence-based review. BMJ Open, 5(6). https://doi.org/10.1136/bmjopen-2014-007199
Panteli, D., Arickx, F., Cleemput, I., Dedet, G., Eckhardt, H., Fogarty, E., Gerkens, S., Henschke, C., Hislop, J., Jommi, C., Kaitelidou, D., Kawalec, P., Keskimaki, I., Kroneman, M., Lopez Bastida, J., Pita Barros, P., Ramsberg, J., Schneider, P., Spillane, S., … Busse, R. (2016). Pharmaceutical regulation in 15 European countries review. Health Systems in Transition, 18(5), 1–122.
Pearson, I., Rothwell, B., Olaye, A., & Knight, C. (2018). Economic Modeling Considerations for Rare Diseases. Value in Health, 21, 515–524. https://doi.org/https://doi.org/10.1016/j.jval.2018.02.008
Postma, M. J., Noone, D., Rozenbaum, M. H., Carter, J. A., Botteman, M. F., Fenwick, E., & Garrison, L. P. (2022). Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? Orphanet Journal of Rare Diseases, 17(1), 1–8. https://doi.org/10.1186/s13023-022-02283-z
Qi, X., Xu, J., Shan, L., Li, Y., Cui, Y., Liu, H., Wang, K., Gao, L., & Zheng Kang1, 2 and Qunhong Wu. (2021). Economic burden and health related quality of life of ultra-rare Gaucher disease in China. Orphanet Journal of Rare Diseases, 16(358).
Simoens, S. (2011). Pricing and reimbursement of orphan drugs: The need for more transparency. Orphanet Journal of Rare Diseases, 6(1), 42. https://doi.org/10.1186/1750-1172-6-42
Simoens, S., Abdallah, K., Barbier, L., Lacosta, T. B., Blonda, A., Car, E., Claessens, Z., Desmet, T., De Sutter, E., Govaerts, L., Janssens, R., Lalova, T., Moorkens, E., Saesen, R., Schoefs, E., Vandenplas, Y., Van Overbeeke, E., Verbaanderd, C., & Huys, I. (2022). How to balance valuable innovation with affordable access to medicines in Belgium? Frontiers in Pharmacology, 13(September), 1–17. https://doi.org/10.3389/fphar.2022.960701
Simoens, S., Cassiman, D., Picavet, E., & Dooms, M. (2011). Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs. Drugs and Therapy Perspectives, 27(10), 24–26. https://doi.org/10.2165/11601640-000000000-00000
Taruscio, D., Capozzoli, F., & Frank, C. (2011). Rare diseases and orphan drugs. Ann Dellstituto Super Santa, 47, 83–93.
Teerawattananon, Y., Painter, C., Dabak, S., Ottersen, T., Gopinathan, U., Chola, L., Chalkidou, K., & Culyer, A. J. (2021). Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making. Cost Effectiveness and Resource Allocation, 19(1), 1–8. https://doi.org/10.1186/s12962-021-00308-1
Tumiene, B., & Graessner, H. (2021). Rare disease care pathways in the EU: from odysseys and labyrinths towards highways. Journal of Community Genetics, 231–239. https://doi.org/10.1007/s12687-021-00520-9
Villa, F., Tutone, M., Altamura, G., Antignani, S., Cangini, A., Fortino, I., Melazzini, M., Trotta, F., Tafuri, G., & Jommi, C. (2019). Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency. Health Policy, 123(6), 595–600. https://doi.org/10.1016/j.healthpol.2019.03.009
Wherry, K., Williamson, I., Chapman, Ri. H., & Kuntz, K. M. (2020). Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients with the G551D Gating Mutation. Value in Health, 23(10), 1332–1339.
Yang, G., Cintina, I., Pariser, A., Oehrlein, E., Sullivan, J., & Kennedy, A. (2022). The national economic burden of rare disease in the United States in 2019. Orphanet Journal of Rare Diseases, 17(1), 1–11. https://doi.org/10.1186/s13023-022-02299-5
Zimmermann, M., Lubinga, S. J., Banken, R., Rind, D., Cramer, G., Synnott, P. G., Chapman, R. H., Khan, S., & Carlson, J. (2019). Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. Value in Health, 22(2), 161–167. https://doi.org/10.1016/j.jval.2018.09.2841
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.